Syquant Capital’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
Other funds holding ABCL
BBA
Syquant Capital's ABCL Position: Q3 2021 in Review
Syquant Capital sold out of AbCellera Biologics (ABCL) in Q3 2021, closing a stake of 70,000 shares — an estimated $1.54M sold.
Syquant Capital first reported a position in ABCL in Q2 2021 and held it in 1 quarter. The position peaked at $1.54M in Q2 2021. 116 funds tracked by Wall St. Rank hold ABCL as of Q3 2021.
- Syquant Capital reported no remaining AbCellera Biologics position as of Q3 2021 after selling out during the quarter.
- Syquant Capital sold 70,000 AbCellera Biologics shares in Q3 2021, an estimated $1.54M.
- Syquant Capital first reported a position in AbCellera Biologics in Q2 2021 and held it in 1 quarter.
- Syquant Capital's AbCellera Biologics position peaked at $1.54M in Q2 2021.
- 116 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2021.
Based on Syquant Capital's 13F filing for Q3 2021, filed 14 Oct 2021.